IXICO excels in delivering HD imaging using advanced imaging biomarkers that quantify key HD measurements, such as caudate nucleus and putamen atrophy, white matter integrity changes, and striatal susceptibility changes. Used in combination with the IXI™ Platform, this enhances our accuracy and efficacy for measuring disease-specific changes in brain region volumetrics.
With a proven track record in HD clinical trials and collaborations with key scientific institutions, such as University College London (UCL) and the CHDI Foundation, IXICO’s combination of disease-specific approaches, tools and technologies, together with deep scientific expertise, has enabled IXICO to build a reputation as the trusted partner for HD clinical trials.
Diffusion MRI (Tensor Imaging, Neurite Orientation Dispersion and Density Imaging, Free Water Imaging, Structural Connectivity)
Magnetic Resonance Spectroscopy (MRS) for brain metabolic levels, Quantitative Susceptibility Mapping (QSM) to measure regional susceptibility
Functional Connectivity and Metabolism.
Regional brain atrophy (Caudate Nucleus, Putamen, Whole Brain, Lateral Ventricles).
Comparison of two natural history studies as part of the HD-IH consortium
Presented at HDTC 2025
Neuroimaging to Facilitate Clinical Trials in Huntington’s Disease: Current Opinion from the EHDN Imaging Working Group - IOS Press
Volumetric change across the different Stages of the Huntington’s disease Integrated Staging System (HD-ISS) defined at baseline
Presented at EHDN 2024
Association between regional volume change and clinical change in Huntington’s disease HD-ISS Stage 2 and Stage 3 participants
Presented at HDTC 2023